Who Loves Ya, Baby?
WHEN KOJAK FIRST HIT TELEVISION SCREENS in 1973, prime time was already flooded with police shows—Columbo, Adam-12 and Hawaii Five-0, to name a few. The new drama didn’t seem to have much to set it...
View ArticleHope and Endurance
A SMALL PLAQUE hanging in the home of Randy and Ellen Layne contains a familiar saying: “Love is patient. Love is kind. Hopes all things. Endures all things. LOVE NEVER FAILS.” A plaque that hangs in...
View ArticleNew Tactics for Bladder Cancer
WHEN KARL PRITCHARD noticed blood in his urine one morning in February 2014, he made an appointment with his primary care doctor. The doctor told Pritchard, who was 76 years old at the time, that if...
View ArticleImmunotherapy Indications Withdrawn
In December 2020, Bristol Myers Squibb announced the withdrawal of the immune checkpoint inhibitor Opdivo (nivolumab) from the U.S. market for the treatment of patients with metastatic small cell...
View ArticleRising to the Challenge
ON AND OFF FOR MORE THAN A YEAR, James R. Scott had noticed blood in his urine. Each time, he checked in with his primary care provider and received a prescription for an antibiotic to treat a...
View ArticleNew Chemotherapy Delivery Device in Bladder Cancer
INTRAVESICAL BACILLUS CALMETTE-GUERIN (BCG), a form of immunotherapy delivered directly to the bladder via a catheter, is the standard of care for patients with high-risk non-muscle-invasive bladder...
View ArticleNon-surgical Options in Bladder Cancer
FOR DECADES, the standard of care for muscle-invasive bladder cancer has been chemotherapy to shrink the tumor followed by surgery to remove the bladder. But a recent clinical trial found adding...
View ArticleCombination Therapy in Advanced Bladder Cancer
FOR DECADES, patients with advanced urothelial cancer—a type of bladder cancer that begins in the cells that line the bladder—received platinum-based chemotherapy as the standard of care. However, in...
View ArticleImmunotherapy Improves Survival in Bladder Cancer
NEW STUDY RESULTS SHOW that adding an immunotherapy drug called Imfinzi (durvalumab) to treatment with chemotherapy and surgery improved event-free survival and overall survival in patients with...
View Article